Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2005-07-26
2005-07-26
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C424S204100, C424S205100, C424S199100, C435S006120, C435S320100
Reexamination Certificate
active
06921535
ABSTRACT:
The present invention relates i.a. to Bovine Respiratory Syncytial Viruses that are not capable of expressing a functional SH-protein and/or G-protein due to a mutation in the genes encoding the said proteins. Furthermore, the invention relates to vaccines based upon such Bovine Respiratory Syncytial Viruses and to methods for the preparation of such vaccines. Also the invention relates to diagnostic test kits for discriminating wild-type Bovine Respiratory Syncytial Viruses from Bovine Respiratory Syncytial Viruses according to the invention and to methods for the discrimination between those viruses.
REFERENCES:
patent: 6033886 (2000-03-01), Conzelmann
patent: 6699476 (2004-03-01), Collins et al.
patent: 0702085 (1996-12-01), None
patent: 0 974 660 (2000-01-01), None
patent: 98 02530 (1998-01-01), None
Whitehead S. S. et al: “Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees.”; Journal of Virology, vol. 73, No. 4, Apr. 1999; pp. 3438-3442.
Karger A. et al: “Recombinant bovine respiratory syncytial virus with deletions of the G or SH genes: G and F proteins bind heparin”; Journal of General Virology, vol. 82, No. 3, Mar. 2001; pp. 631-640.
Karron R. A. et al: “Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: Clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant”; Proceedings of the National Academy of Sciences of the United States, vol. 94, No. 25, Dec. 9, 1997, pp. 13961-13966.
Buchholz U. J. et al: “Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): Effects on host range and evaluation as a live-attenuated HRSV vaccine.” Journal of Virology, vol. 74, No. 3, Feb. 2000, pp. 1187-1199.
Dudas R. A. et al: “Respiratory syncytial virus vaccines”, Clinical Microbiology Reviews, vol. 11, No 3, Jul. 1998, pp. 430-439.
Whitehead S.S. et al: “Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with thos of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates”, Journal of Virology, vol. 73, No 12, Dec. 1999, pp. 9773-9780.
Buchholz Ursula J.
Schmidt Ulrike
Akzo Nobel N.V.
Milstead Mark W.
Salimi Ali R.
LandOfFree
Attenuated Bovine Respiratory Syncytial virus does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Attenuated Bovine Respiratory Syncytial virus, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Attenuated Bovine Respiratory Syncytial virus will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3397144